Structure base drug discovery company
Amura Holdings Ltd., Minerva Building, Babraham Research Campus, Babraham, CB22 3AT, U.K.
Home
Company
Technologies
Programmes
News
Contact
Sitemap
Search
 
 
     
 

Welcome to Amura

 leaders in protease inhibitor design

Amura is a company dedicated to the development of protease inhibitors. Our key invention is  a new chemical solution for the inhibition of the mammalian cathepsins, an  important family of enzymes that are implicated in many diseases. Our second key asset is a broad spectrum  ß-lactamase inhibitor,  that is an ideal combination partner for resistance susceptible ß-lactam antibiotics.

Amura's AMcore™ scaffold is the premier chemical solution to cathepsin inhibitor design, generating compounds that are highly potent, specific, orally active and drug-like. Candidates based around the AMcore™ scaffold have addressed the problems inherent in competitor cathepsin inhibitors, providing Amura with a significant advantage for clinical assessment and commercialization in numerous attractive therapeutic indications.

Our development candidates for cathepsin S (AM-3840), K (AM-3701) and a mixed S/K profile (AM-3876) are ready for GMP synthesis, regulatory safety studies and clinical assessment giving a wealth of opportunities in large market indications such as  chronic neuropathic pain, autoimmunity (e.g. rheumatoid arthritis), osteoporosis, osteoarthritis, bone metastasisand malaria.  Notably, our cathepsin K inhibitor AM-3701 has the potential to treat both of the major arthritic diseases.

Amura will leverage its resources and capabilities to secure strategic alliances with globally-recognised licensing partners thereby generating shareholder value.

 

 

 
Email: amura@amura.co.uk
Phone: +44(0)1223 839797 Fax: +44(0)1223 839898 Copyright © 2009 Amura Holdings Ltd.
Powered by www.dotscoms.co.uk